CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 80.96% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Richter shares hit record high after Lilly licensing deal

By Reuters News

BUDAPEST, Nov 12 (Reuters) - Shares in Hungarian drugmaker Gedeon Richter GDRB.BU hit an all-time high on Thursday after the company announced an exclusive licensing deal with Eli Lilly to develop therapies combining Richter's estetrol with Lilly medicines.

Analysts said the agreement could help Richter develop another major revenue-generating product as it gets ready for the expiry of patent protection in 2030 for cariprazine, its flagship antipsychotic sold as Vraylar in the United States by AbbVie.

  • Richter's shares GDRB.BU were up 2.4% by 0948 GMT.

  • The deal gives Lilly exclusive, worldwide rights to develop, manufacture and commercialize medicines combining Richter's E4 — a native estrogen approved in the European Economic Area as Fylrevy for hormone replacement therapy — with Lilly compounds for women's health and cardiometabolic diseases

  • Lilly will also have an option to co-commercialize Fylrevy in the US upon regulatory approval.

  • Richter is eligible for regulatory and commercial milestone payments and tiered royalties on net sales.

  • Lilly will make an upfront cash payment on closing and will separately acquire 381,354 Richter treasury shares for approximately $15 million, at about $39.33 per share.

  • "The oestrogen replacement therapy could become a high-revenue product and partly offset the decline in Vraylar sales expected from 2030," Erste analysts wrote in a note.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.